Compare ANIP & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | LMAT |
|---|---|---|
| Founded | 2001 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2006 |
| Metric | ANIP | LMAT |
|---|---|---|
| Price | $77.36 | $87.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $107.33 | $101.83 |
| AVG Volume (30 Days) | ★ 419.1K | 129.5K |
| Earning Date | 02-27-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | N/A | ★ 27.40 |
| EPS | 1.67 | ★ 2.32 |
| Revenue | ★ $826,880,000.00 | $240,866,000.00 |
| Revenue This Year | $44.19 | $15.17 |
| Revenue Next Year | $11.25 | $9.07 |
| P/E Ratio | $46.19 | ★ $37.79 |
| Revenue Growth | ★ 48.87 | 13.07 |
| 52 Week Low | $54.10 | $71.42 |
| 52 Week High | $99.50 | $105.55 |
| Indicator | ANIP | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 56.35 |
| Support Level | $75.30 | $85.39 |
| Resistance Level | $83.80 | $88.50 |
| Average True Range (ATR) | 2.51 | 1.96 |
| MACD | -0.54 | 0.10 |
| Stochastic Oscillator | 20.59 | 79.56 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.